On May 16, the US Food and Drug Administration granted accelerated approval to tarlatamab-dlle for extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
For more information read the FDA announcement and the Amgen Inc. announcement.
Posted 5/20/2024
From challenging misconceptions about breast cancer to incorporating paramedical tattooing for survivors after reconstruction, gather valuable takeaways from Oncology Issues in observance of Breast Cancer Awareness Month.
